View Item 

Show simple item record

Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease
dc.contributor.authorCohen, Robert M.en_US
dc.contributor.authorSunderland, Treyen_US
dc.contributor.authorLawlor, Brian A.en_US
dc.contributor.authorCohen, Martin Robert.en_US
dc.contributor.authorMurphy, Dennis L.en_US
dc.contributor.authorNewhouse, Paul A.en_US
dc.contributor.authorHill, James L.en_US
dc.contributor.authorMellow, Alan M.en_US
dc.date.accessioned2006-09-11T17:47:43Z
dc.date.available2006-09-11T17:47:43Z
dc.date.issued1989-07en_US
dc.identifier.citationMellow, Alan M.; Sunderland, Trey; Cohen, Robert M.; Lawlor, Brian A.; Hill, James L.; Newhouse, Paul A.; Cohen, Martin R.; Murphy, Dennis L.; (1989). "Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease." Psychopharmacology 98(3): 403-407. <http://hdl.handle.net/2027.42/46449>en_US
dc.identifier.issn1432-2072en_US
dc.identifier.issn0033-3158en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46449
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2501817&dopt=citationen_US
dc.description.abstractThyrotropin releasing hormone (TRH) was administered intravenously to ten patients with Alzheimer's Disease (AD) in a high-dose paradigm, thought to maximize central nervous system effects and potentially produce facilitation of cholinergic function, a known property of the neuropeptide. Acute effects of TRH on behavioral, cognitive and physiologic measures were assessed after patients received 0.1 mg/kg TRH, 0.3 mg/kg TRH and placebo, the higher TRH dose and placebo being given in a randomized, double-blind fashion. Patients showed statistically significant increases in arousal and improvement in affect, as well as a modest improvement in semantic memory, all after receiving the higher TRH dose. Both TRH doses produced transient rises in systolic blood pressure, with no effect on diastolic blood pressure, heart rate or temperature. This study suggests that high-dose TRH can be safely administered to AD patients and is neurobehaviorally active; further studies are needed to determine the extent and mechanism of the cognitive and psychobiological properties of this peptide in AD and other neuropsychiatric disorders.en_US
dc.format.extent602744 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherThyrotropin Releasing Hormoneen_US
dc.subject.otherNeuropeptidesen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPsychiatryen_US
dc.subject.otherAlzheimer's Diseaseen_US
dc.titleAcute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's diseaseen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUnit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USA; Neuroscience Laboratory, University of Michigan, 1103 East Huron, 48104-1687, Ann Arbor, MI, USA; Department of Psychiatry, University of Michigan Medical Center, 48109, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherSection on Clinical Brain Imaging, Laboratory of Cerebral Metabolism, National Institute of Mental Health, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherEnsor Research Laboratory, William S. Hall Psychiatric Institute, University of South Carolina School of Medicine, 29028, Columbia, SC, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USA; Department of Psychiatry, University of Vermont College of Medicine, 05405, Burlington, VT, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2501817en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46449/1/213_2004_Article_BF00451695.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00451695en_US
dc.identifier.sourcePsychopharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
213_2004_Article_BF00451695.pdf
Size:
588.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.